effectiveness of immunotherapy in Indonesian children with rhinosinusitis

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20191001002

Enrollment

Registered

2019-10-01

Start date

2019-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

children with rhinosinusitis coused by house duat mite allergy

Interventions

House dust mite exctract immunotherapy and allergy medicines if necessary,Allergy medicines only with no house dust mite exctract immunotherapy

Experimental Biological/Vaccine,Experimental Drug

Subcutaneous injection immunotherapy,Allergy Medicines

Eligibility

Sex/Gender

All

Age

4 Years to 18 Years

Inclusion criteria

Inclusion criteria: age: 3.5-18 years with chronic rhinosinusitis caused by house dust mite allergy

Exclusion criteria

Exclusion criteria: mental retatdation infection anatomic anomali of the nose

Design outcomes

Primary

Measure	Time frame
Effectivenessof immunotherapy 14 weeks questionnaire	—

Secondary

Measure	Time frame
recovery from rhinosinusitis 14 weeks wate's photo x-ray	—

Countries

Indonesia

Contacts

Public ContactAnang Endaryanto

Indonesian Pediatric Allergy Immunology

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026